Published in N Engl J Med on June 29, 2000
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer | NCT02343614
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A (2004) 5.89
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Prostaglandins and cancer. Gut (2005) 3.44
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol (2003) 3.06
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev (2003) 2.76
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA (2016) 2.68
The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest (2005) 2.62
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog (2011) 2.30
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Familial adenomatous polyposis. Orphanet J Rare Dis (2009) 2.21
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) (2010) 1.91
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 1.90
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 1.84
Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J (2005) 1.80
Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J (2008) 1.78
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst (2015) 1.77
Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet (2004) 1.73
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci U S A (2002) 1.67
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) (2011) 1.62
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A (2002) 1.61
Dietary intake of fish, ω-3 and ω-6 fatty acids and risk of colorectal cancer: A prospective study in U.S. men and women. Int J Cancer (2014) 1.60
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol (2010) 1.51
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer (2010) 1.51
Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer (2002) 1.49
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol (2009) 1.40
Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo) (2012) 1.37
Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy (2010) 1.37
Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta (2008) 1.36
Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol (2011) 1.34
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg (2001) 1.30
Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci (2000) 1.30
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res (2006) 1.28
The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis (2006) 1.27
Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol (2008) 1.26
Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle (2012) 1.26
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res (2005) 1.22
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol (2001) 1.22
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.20
Cancer chemoprevention: a rapidly evolving field. Br J Cancer (2013) 1.20
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol (2002) 1.19
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer (2009) 1.19
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer (2012) 1.15
Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis (2010) 1.15
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest (2009) 1.14
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol (2006) 1.13
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest (2001) 1.13
Targeted therapy for breast cancer prevention. Front Oncol (2013) 1.12
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Colonic polyps in children and adolescents. Can J Gastroenterol (2007) 1.12
The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J (2006) 1.11
Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol (2012) 1.11
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs (2005) 1.11
Surveillance and management of upper gastrointestinal disease in Familial Adenomatous Polyposis. Fam Cancer (2006) 1.11
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther (2013) 1.10
Endoscopic imaging and size estimation of colorectal adenomas in the multiple intestinal neoplasia mouse. Gastrointest Endosc (2009) 1.10
HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol (2011) 1.10
Drug repurposing: far beyond new targets for old drugs. AAPS J (2012) 1.09
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer (2008) 1.09
Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res (Phila) (2011) 1.08
Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest (2014) 1.07
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg (2005) 1.07
LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis (2013) 1.06
Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res (2011) 1.06
New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila) (2013) 1.05
Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol (2007) 1.03
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
Familial adenomatous polyposis: The practical applications of clinical and molecular screening. Fam Cancer (2006) 1.02
Colonic adenomatous polyposis syndromes: clinical management. Clin Colon Rectal Surg (2008) 1.02
COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res (2013) 1.02
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev (1999) 13.43
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst (1994) 7.91
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Persistent pain and faecal urgency after stapled haemorrhoidectomy. Lancet (2000) 7.09
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med (2001) 7.07
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev (1990) 6.00
Assessment and comparison of prognostic classification schemes for survival data. Stat Med (1999) 5.94
Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol (2000) 5.66
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
A family of human cdc2-related protein kinases. EMBO J (1992) 4.96
Isolation of a Miller-Dieker lissencephaly gene containing G protein beta-subunit-like repeats. Nature (1993) 4.87
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA (1996) 4.80
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin (2001) 4.41
Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol (1995) 4.22
Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry (2001) 4.13
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet (2009) 3.99
Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet (2008) 3.87
Tracing the stepwise oxygenation of the Proterozoic ocean. Nature (2008) 3.85
Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet (1989) 3.84
Local recurrence following 'curative' surgery for large bowel cancer: I. The overall picture. Br J Surg (1984) 3.82
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology (1993) 3.76
A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med (1992) 3.70
Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science (1992) 3.58
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Incidence and origin of "null" alleles in the (AC)n microsatellite markers. Am J Hum Genet (1993) 3.18
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene (2006) 3.10
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst (1997) 3.03
Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg (1966) 3.00
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg (1992) 2.98
Desmoids in familial adenomatous polyposis. Br J Surg (1996) 2.94
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer (1998) 2.91
Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health (2003) 2.90
American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin (1997) 2.89
The trephine colostomy: a permanent left iliac fossa end colostomy without recourse to laparotomy. Ann R Coll Surg Engl (1991) 2.84
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol (2004) 2.83
Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology (1981) 2.75
Localization of avian tumor virus group-specific antigen in cell and virus. Virology (1966) 2.70
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Life table analysis of stomal complications following colostomy. Dis Colon Rectum (1994) 2.66
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem (1997) 2.66
Malignant large bowel obstruction. Br J Surg (1985) 2.62
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology (1990) 2.58
Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood (2001) 2.57
Methylmalonic aciduria. An inborn error of metabolism leading to chronic metabolic acidosis. Arch Dis Child (1967) 2.56
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res (1995) 2.56
The group-specific antigen and other structural proteins of hamster and mouse C-type viruses. Virology (1971) 2.46
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43
White matter damage on diffusion tensor imaging correlates with age-related cognitive decline. Neurology (2006) 2.42
The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A (1999) 2.41
A prospective randomized trial of cannulation technique in ERCP: effects on technical success and post-ERCP pancreatitis. Endoscopy (2008) 2.40
DSPP mutation in dentinogenesis imperfecta Shields type II. Nat Genet (2001) 2.39
Susceptibility of human peripheral blood dendritic cells to infection by human immunodeficiency virus. J Gen Virol (1987) 2.38
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg (1996) 2.35
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A (1988) 2.34
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature (1986) 2.32
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys (1999) 2.29
A gender-specific HIV/STD risk reduction intervention for women in a health care setting: short- and long-term results of a randomized clinical trial. AIDS Care (2002) 2.28
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther (1994) 2.27
Metachronous carcinoma of the large intestine and intestinal polyps. Proc R Soc Med (1967) 2.26
Control of asthma in Canada: failure to achieve guideline targets. Can Respir J (2001) 2.26
Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ (2001) 2.25
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Argon plasma coagulation in chronic radiation proctitis. Endoscopy (2007) 2.23
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Are deprivation indicators a proxy for morbidity? A comparison of the prevalence of arthritis, depression, dyspepsia, obesity and respiratory symptoms with unemployment rates and Jarman scores. J Public Health Med (1993) 2.22